Blood clotting drug studied for Chemo-Related bleeding – trial halted early
NCT ID NCT05091684
First seen Jan 09, 2026 · Last updated May 14, 2026 · Updated 24 times
Summary
This study looked at whether a clotting drug called fibrinogen concentrate could help control bleeding in blood cancer patients whose platelet counts are very low after chemotherapy and who don't respond to platelet transfusions. Only one person took part before the study was stopped early. The goal was to measure how well the blood could clot after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLEEDING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Saint-Etienne
Saint-Etienne, 42055, France
Conditions
Explore the condition pages connected to this study.